Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4268652

COc1cccc(OC)c1OC.N

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.58
CA1 P00915 4/20 0.58
CA2 P00918 4/20 0.58
CA9 Q16790 4/20 0.58
CA7 P43166 3/20 0.58
CA12 O43570 2/20 0.58
CA14 Q9ULX7 2/20 0.58
CA4 P22748 1/20 0.58
NFE2L2 Q16236 5/20 0.50
ALDH1A1 P00352 2/20 0.50
TP53 P04637 2/20 0.50
CYP3A4 P08684 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
ALOX12 P18054 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL151213 0.97 CA1 (0.61) SMN1; SMN2CA1CA2CA9CA7
SCHEMBL25434306 0.97 CA1 (0.61) SMN1; SMN2CA1CA2CA9CA7
SCHEMBL27753904 0.97 CA1 (0.61) SMN1; SMN2CA1CA2CA9CA7
SCHEMBL27731704 0.94 SMN1; SMN2 (0.58) SMN1; SMN2CA1CA2CA9CA7
Hydrochloric Acid SCHEMBL31658961 0.94 SMN1; SMN2 (0.58) SMN1; SMN2CA1CA2CA9CA7
Bromide SCHEMBL28158222 0.94 SMN1; SMN2 (0.58) SMN1; SMN2CA1CA2CA9CA7
Bromomethane SCHEMBL27848237 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CA1CA2CA9CA7
Methylamine SCHEMBL27494863 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CA1CA2CA9CA7
Bromide SCHEMBL1307432 0.92 SMN1; SMN2 (0.56) SMN1; SMN2CA1CA2CA9CA7
SCHEMBL31666382 0.89 SMN1; SMN2 (0.54) SMN1; SMN2CA1CA2CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579356-B2 Thia-tetraazaacenaphthylene kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-08-25 US disclosed
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-15 US disclosed
WO-2006118749-A1 THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265264-A1 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide ADK, MAP3K9, MAP4K5 SMN1; SMN2 4156/4885CA1 3864/4885CA2 1007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.